Stock Quote
Vical Inc (VICL.W) (NASD ADF)
sector: Healthcare .
industry: Pharmaceuticals - Generic & Specialty ยท
View VICL on other exchanges
$3.20
11 Nov 2009
+0.63%
$3.18
$3.20
100
$3.20
$3.20
$5.51
$1.04
1.62
549,083
VICL.W
More News
| Press Releases
| Key Developments
| Name | Current Position | Compensation |
|---|---|---|
| Douglas, R. Gordon | Chairman of the Board | -- |
| Samant, Vijay | President, Chief Executive Officer, Director | 1,183,140 |
| Broadfoot, Jill | Chief Financial Officer, Senior Vice President, Secretary | 539,123 |
Profile
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of serious or life-threatening diseases. The Company has three active independent development programs in the areas of infectious... Full Description
Company Address
Vical Inc
10390 Pacific Center Court
San Diego CA 92121
P: +1858.6461100
F: +1858.6461150
10390 Pacific Center Court
San Diego CA 92121
P: +1858.6461100
F: +1858.6461150
Analyst Research
Performance of Key Competitors
| Company | Price | Change |
|---|---|---|
| Sanofi-Aventis SA | €51.77 | +1.40 |
| Novartis AG | CHF55.15 | +1.20 |
| GlaxoSmithKline plc | £1,277.50 | +24.00 |
| VICL.W | Industry | |
|---|---|---|
| P/E(TTM) | -- | 3.57 |
| P/S(TTM) | 12.47 | 0.57 |
| ROI(TTM) | -50.67 | 1.86 |
| ROE(TTM) | -52.84 | 2.51 |
| Consensus Recommendation | Outperform |
|---|---|
| EPS Est. (Current Period) | -0.17 |
| EPS Est. (Current Year) | -0.60 |
| Total Revenue | $3.90M |
| Net Income | $-6.99M |
| EPS | $-0.14 |
